PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
about
Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging.Rho GTPase effectors and NAD metabolism in cancer immune suppression.Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas: A case report and review of the literatures.Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers.Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.Biology of Bone Sarcomas and New Therapeutic Developments.New agents for the management of resistant metastatic breast cancer.Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning.Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship.TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures.Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.Anti-human SIRPα antibody is a new tool for cancer immunotherapy.Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma.YAP/TAZ Activation as a Target for Treating Metastatic Cancer.Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets.Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.Immuno-Oncology: Emerging Targets and Combination TherapiesCTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid CancersTumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune EvasionThe Role of Immune Escape and Immune Cell Infiltration in Breast CancerIn tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptoticThe IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapyRedox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatmentBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitorsOptimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapyImmune Checkpoint Inhibitor-Associated Colits and HepatitisDNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial CancerRegulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor MicroenvironmentImmunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients
P2860
Q41670098-561785D8-70F0-481B-A8D6-C47F61626B4EQ45974765-856412FC-E12B-442C-932F-8D0F795D7002Q46166592-DF335D06-811E-48C8-B95E-EC0DFAD4B3E2Q47130162-87782FAB-2F7F-4FBE-A340-F17B772D79B3Q47157402-4C49ACF1-F430-4799-AA00-C2B3C707B848Q47642445-A3CB0489-F8EC-4353-A5C2-79181C2BEB15Q47712161-F800E0F8-69CD-4258-8164-AFE49AE9B5D7Q48120956-8A643F9B-7637-47A6-9D9E-E5062A721F8CQ48240854-EB964578-0AC9-4081-8C3E-3012D090A0D2Q49283462-35824C70-0A48-4936-85FF-3D56951F8F05Q49391681-4DD7484C-BA84-4E3B-804B-214B5B3370FAQ50072085-A9DA064F-478C-4276-8468-DAC091E2ED4CQ52316792-B5EA5B5D-6381-40E4-821A-F4286E6CD55BQ52348476-A5990F07-407E-42D5-B7E0-05D7846602E7Q52661722-23F86C3D-6FF3-4402-88E6-5D1708BA6970Q52688875-D4DFA6FC-0B0F-4F61-8F42-1D05ADF35820Q53834241-9AA40C13-7D55-4EAB-B2F8-FBAEE2CE956BQ54977387-B8E1A435-E430-4FB5-B349-4E909A698574Q55040688-1F3473F8-FB13-4A67-BB3A-BE46575C25CAQ55142863-DFEA6EB7-8ADB-45CD-ADCD-A73E1012D8C1Q55174561-190A44E8-FC82-4180-BD10-EC3A64BCB5ECQ55287125-54CCA718-60AD-4D5B-A447-93C236B0E177Q55311835-6FB00F88-8166-4339-A079-8F6988BE4231Q55401761-472E2F9D-FA44-4A14-BB04-F4D78CB00532Q55436995-57DBBA01-5491-40CB-9AF5-921C6BACB4D3Q55510561-C69659DC-0144-4E55-B5D6-3B5D187B6F7EQ55518179-102BA156-F66C-4420-991D-910B65491222Q56889817-5CEE6433-8AF6-4519-AC25-A72C61EEF021Q56891239-95C68DEE-32A0-4E23-AA11-E8D46614A437Q57072897-F17AC366-35C5-42DA-A8F1-2EA5EEA3386AQ57114285-F910BD85-3706-486D-8B60-9B6386DE085AQ57821568-CA0B1743-ECE8-4995-BA2E-395D1F900DA5Q58545762-A0944D41-22AD-4E01-A840-DF2C2E7AF4C2Q58699598-AA7552C9-37D4-4892-944D-D309D1F7B8DCQ58713932-2770256E-265E-4B98-82AB-09582EAA18D2Q58719363-5780216C-6E92-44E8-A8AD-9FD99EBD8C86Q58721137-F8BA2662-8C9E-4C35-9460-EC7AA516C3AEQ58726243-7EBC56F2-84D7-466D-A60B-AF4452E84616Q58773649-AC045DC6-2F14-4E8C-8393-7240B1F25FDDQ58804408-F2A0238F-FB33-4619-8E41-DD72F9B51317
P2860
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
PD-1 and PD-L1 Checkpoint Sign ...... nations, and Clinical Outcome.
@en
type
label
PD-1 and PD-L1 Checkpoint Sign ...... nations, and Clinical Outcome.
@en
prefLabel
PD-1 and PD-L1 Checkpoint Sign ...... nations, and Clinical Outcome.
@en
P2093
P2860
P356
P1476
PD-1 and PD-L1 Checkpoint Sign ...... inations, and Clinical Outcome
@en
P2093
Arun K Iyer
Hashem O Alsaab
Katyayani Tatiparti
Ketki Bhise
Rami Alzhrani
Sushil K Kashaw
P2860
P356
10.3389/FPHAR.2017.00561
P50
P577
2017-08-23T00:00:00Z